RAM Investment Partners LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

RAM Investment Partners LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to its most recent filing with the SEC. The firm purchased 1,072 shares of the company’s stock, valued at approximately $210,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZTS. Webster Bank N. A. boosted its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Quarry LP boosted its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares in the last quarter. LRI Investments LLC acquired a new stake in Zoetis in the 1st quarter valued at about $43,000. Central Valley Advisors LLC purchased a new position in Zoetis during the 2nd quarter valued at about $49,000. Finally, Future Financial Wealth Managment LLC acquired a new position in Zoetis during the first quarter worth about $51,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS opened at $188.99 on Thursday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company’s 50 day simple moving average is $189.23 and its 200 day simple moving average is $177.58. The stock has a market capitalization of $85.62 billion, a PE ratio of 36.98, a P/E/G ratio of 2.94 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the business earned $1.41 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.91%. Zoetis’s dividend payout ratio (DPR) is 33.86%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. BTIG Research raised their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler upped their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.